Letters

Mibefradil was not rushed to market in United States

BMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7213.852a (Published 25 September 1999) Cite this as: BMJ 1999;319:852
  1. Robert R Fenichel, deputy division director (fenichel@cder.fda.gov)
  1. Division of Cardio-Renal Drug Products, Food and Drug Administration, HFD-110, 5600 Fishers Lane, Rockville, MD 20857, USA

    EDITOR—Landow gave a misleading impression of the discussion about mibefradil at the US Food and Drug Administration's Cardio-Renal Advisory Committee meeting of 28 February 1997 and the subsequent withdrawal of the drug from the market in the United States.1

    The question most extensively discussed at the meeting was whether mibefradil prolongs the QT interval and is therefore likely to induce malignant ventricular arrhythmia. …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe